DocGo Inc. Stock News

DocGo was rewarded a no-bid contract by the NYC to provide medical care for the migrants, but this large contract is facing the risk of being revoked as of late. The management took the direction to b

DocGo improved revenue in the second quarter. The company has added major contracts this year with EmblemHealth and Carnival Cruise Lines.

NEW YORK--(BUSINESS WIRE)--DocGo Inc (Nasdaq: DCGO), a leading provider of last-mile mobile health services, announced today that Anthony Capone, Chief Executive Officer will present at three differen

DocGo Inc. (NASDAQ:DCGO ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Corporate Participants Mike Cole - Director-Investor Relations Anthony Capone - Chief Executive Officer Lee Biensto

DocGo Inc. (DCGO) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.07 per share a year ago.

Two new Breakout Stocks for Week 31 curated by the MDA model for 10% short-term upside and additional model selections. This week two of four picks gained over 10% in less than a week with peak gains

NEW YORK--(BUSINESS WIRE)--DocGo Inc., a leading provider of last-mile mobile health services (Nasdaq: DCGO), today announced that the company will report results for the second quarter ended June 30,

DocGo Inc. (DCGO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the

DocGo delivered what analysts at Canaccord called “mixed” results, but that was enough for the firm to reiterate its Buy rating and $13 price target.  “At first glance, DocGo's 1Q results can b

DocGo, Inc. (DGCO) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Mike Cole – Director-Investor Relations Anthony Capone – Chief Executive Officer Lee Bienstock – P

NEW YORK--(BUSINESS WIRE)--DocGo will announce Q1 2023 results on Monday, May 8th, via conference call.

We saw our previous prediction of municipal contracts helping cushion DocGo's revenue (absent of the Covid test) work out for its full year of 2022. The technological advantage in operations and low d

DocGo Inc, a last-mile health services company, continues to prove it can successfully replace its COVID testing revenue after it posted 4Q results that beat expectations, according to analysts at Can

DocGo Inc (NASDAQ: DCGO) has emerged as a buyable growth stock for 2023, which is saying something. The fallout from SVB's collapse is yet to be felt and will impact growth names this year.